Navigation Links
Echo Therapeutics Announces 2010 Financial Results
Date:3/21/2011

tlookEcho Therapeutics' management reiterated its expectations for the 2011 outlook:

"As we continue to build on our positive momentum, we are focused on completing several key milestones during 2011 that we believe will significantly increase shareholder value.  We anticipate a listing on a national exchange in the near-term which will allow us to maximize our outreach to a new, untapped investor base.  Additionally, we hope to gain product clearance for our Prelude System with our licensee Ferndale which will enable the company to begin generating near-term revenue," Dr. Mooney concluded. "This year we plan to aggressively advance our clinical development of our Symphony system, clearing the path for an application to the FDA for marketing clearance. We anticipate securing additional strategic partner licensing arrangements while we begin manufacturing scale-up for Prelude's product validation and planned product launch in the second half of 2011."

About Echo TherapeuticsEcho is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for use in hospital critical care units and for patients with diabetes. Echo is also developing its needle-free Prelude SkinPrep System as a platform technology for enhanced skin permeation for transdermal drug delivery of a wide range of novel topical reformulations of widely-used, FDA-approved products.

Cautionary Statement Regarding Forward Looking StatementsThe statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements.  Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo's and its licensees' ongoing studies, including the ef
'/>"/>

SOURCE Echo Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... , March 5, 2015   AMC ... management solutions recognized for improving the effectiveness and ... that Robert Anazagasty and Jared ... serve as Vice President, Strategic Client Development, and ... These additions support AMC Health,s commitment to accelerating ...
(Date:3/5/2015)... -- LUNGevity Foundation, the nation,s leading lung cancer ... approval of Bristol Myers Squibb,s new immunotherapy drug ... another critical new treatment option to fight lung ... own immune system to fight cancerous cells. Importantly, ... with squamous cell lung cancer, a population for ...
(Date:3/5/2015)... PRINCETON, N.J. , March 5, 2015 ... late stage biopharmaceutical company committed to developing products that ... oncology and biodefense, announced today that its President and ... will give a corporate presentation at the 27 th ... California , on Tuesday, March 10, 2015 at ...
Breaking Medicine Technology:AMC Health Bolsters Sales Team with Robert Anazagasty and Jared Wilstead 2AMC Health Bolsters Sales Team with Robert Anazagasty and Jared Wilstead 3LUNGevity Foundation Applauds FDA Approval of Immunotherapy Drug Opdivo 2LUNGevity Foundation Applauds FDA Approval of Immunotherapy Drug Opdivo 3Soligenix to Present at the 27th Annual ROTH Conference 2Soligenix to Present at the 27th Annual ROTH Conference 3
... clinical research data suggests that [18F] Flutemetamol could add ... provide accurate identification of beta amyloid plaques, considered to ... (AD).  Flutemetamol, a GE Healthcare Positron Emission Tomography (PET) ... studied to identify the uptake of beta amyloid via ...
... 13, 2011 Cumberland Pharmaceuticals Inc. (Nasdaq: ... received approval from the U.S. Food and Drug Administration ... ) Injection, the Company,s product used to treat acetaminophen ... Ethylene diamine tetracetic acid or any other stabilization and ...
Cached Medicine Technology:GE Healthcare Presents Flutemetamol Data for Detection of Amyloid Plaque Linked to Alzheimer's Disease 2GE Healthcare Presents Flutemetamol Data for Detection of Amyloid Plaque Linked to Alzheimer's Disease 3Cumberland Pharmaceuticals Receives FDA Approval for New Formulation of Acetadote 2Cumberland Pharmaceuticals Receives FDA Approval for New Formulation of Acetadote 3Cumberland Pharmaceuticals Receives FDA Approval for New Formulation of Acetadote 4
(Date:3/6/2015)... Dr. Mark Sowell recently returned from leading a three day ... advanced education in the field of dentistry, Spear Education draws ... visiting faculty member of this prestigious institution, Dr. Sowell is ... Spear Education to participate in a specialized workshop. Of the ... the top 10% and those willing to sacrifice to be ...
(Date:3/6/2015)... San Diego, CA (PRWEB) March 06, 2015 ... study findings continue to be discussed, Ford & Associates ... wake of a January 2015 filed lawsuit: Verduzco v. ... Court, Northern District of California. , “In light ... those who have used Benicar to evaluate and explore ...
(Date:3/5/2015)... (PRWEB) March 06, 2015 In 2014, ... being first–in-class. AstraZeneca tops the list scoring 4 drug ... over 25% of all FDA approved drug products, followed ... mechanisms such as anti-PCSK9, anti-PD1 and CDK inhibitors keep ... approved by the FDA to treat metastatic melanoma, and ...
(Date:3/5/2015)... This week, 60 Minutes ... laminate flooring products, initiating widespread concern from homeowners. ... materials made primarily from bamboo, stands behind their ... flooring products for volatile organic compounds (VOCs) through ... (BMH). Results from formaldehyde emissions testing show ...
(Date:3/5/2015)... NY (PRWEB) March 05, 2015 ... forward in a Pennsylvania mass tort litigation currently ... where a jury has begun hearing testimony in ... the atypical antipsychotic medication can cause gynecomastia, or ... case in question was filed on behalf of ...
Breaking Medicine News(10 mins):Health News:Plano Dentist Teaches Dentists from Around the Globe at Spear Education 2Health News:Mayo Clinic's Benicar Case Study Findings Prompts Commentary from Ford & Associates Nationwide Legal Services in Wake of a Recently Filed Benicar Lawsuit 2Health News:Mayo Clinic's Benicar Case Study Findings Prompts Commentary from Ford & Associates Nationwide Legal Services in Wake of a Recently Filed Benicar Lawsuit 3Health News:Mayo Clinic's Benicar Case Study Findings Prompts Commentary from Ford & Associates Nationwide Legal Services in Wake of a Recently Filed Benicar Lawsuit 4Health News:World Pharma Business and Large-Cap Companies Discussed by MP Advisors in In-demand Study Available at MarketPublishers.com 2Health News:World Pharma Business and Large-Cap Companies Discussed by MP Advisors in In-demand Study Available at MarketPublishers.com 3Health News:With Homeowners Concerned About Formaldehyde, Cali Bamboo Puts Safety Above Bottom Line 2Health News:Risperdal Lawsuits Move Forward in Pennsylvania, as Bernstein Liebhard LLP Comments on Start of Second Gynecomastia Trial 2Health News:Risperdal Lawsuits Move Forward in Pennsylvania, as Bernstein Liebhard LLP Comments on Start of Second Gynecomastia Trial 3
... 22 ResMed Inc. (NYSE: RMD ), announced ... its results for the third quarter and nine months of ... with ResMed,s results will be issued after 1:00 p.m. Pacific ... webcast to review its results, market trends, and future outlook.The ...
... study finds older people taking NSAIDs more likely to suffer ... suggested that older people who want to avoid Alzheimer,s disease ... ibuprofen and naproxen, but a new study suggests that might ... ,Should I take these to prevent dementia?, the answer ...
... BALTIMORE, April 22 XLHealth, owner and operator of ... Advantage chronic condition Special Needs Plans, supports the proposed ... in the first of a series of round-table discussions ... The hearing,s focus on using the Medicare system as ...
... professional groups join with Congressional sponsors Reps. Israel, Brady ... access to IVIGWASHINGTON, April 22 Members ... introduction of new legislation - H.R. 2002, Medicare Patient ... inadequate Medicare reimbursements that currently restrict patient access to ...
... Study finds no link to condition that can increase ... Soy isoflavones don,t increase breast density, a new study ... increased breast density is associated with a higher risk ... that dietary factors, including isoflavones (estrogen-like plant compounds) might ...
... New York Times best-selling author and mother of five ... special family gathering to celebrate her status as a mom. Instead, ... seeking favors and just plain hard work. Novak,s 5th Annual Online ... May is a labor of love for her son who has ...
Cached Medicine News:Health News:ResMed Announces Conference Call and Webcast to Discuss Third Quarter 2009 Results 2Health News:Painkillers May Not Protect Against Dementia 2Health News:Painkillers May Not Protect Against Dementia 3Health News:XLHealth Statement on Senate Finance Committee Roundtable on Healthcare Reform 2Health News:New Bill Offers Medicare Reimbursement Fix for Intravenous Immune Globulin 2Health News:New Bill Offers Medicare Reimbursement Fix for Intravenous Immune Globulin 3Health News:New Bill Offers Medicare Reimbursement Fix for Intravenous Immune Globulin 4Health News:NY Times Best-Selling Author Brenda Novak Gives Annual Mother's Day Gift of Hope to Diabetic Son and Others 2Health News:NY Times Best-Selling Author Brenda Novak Gives Annual Mother's Day Gift of Hope to Diabetic Son and Others 3Health News:NY Times Best-Selling Author Brenda Novak Gives Annual Mother's Day Gift of Hope to Diabetic Son and Others 4
4 megapixel zoom digicam with a 4x optical zoom, Effective pixels:4.0 million CCD:1/1.8-in. type (4.13 million total pixels), Max Image size:2272 (2,272 x 1,704 pixels), Lens:4x Zoom-Nikkor; f = 7.85...
... Gene Tech acclaimed GT-CAPTURE digital camera ... most manufacturers microscope such as Olympus, Leica, ... data base and transferring images over the ... 1/1.8-in. CCD and a performance-proven Nikkor lens. ...
... The DN100 is a superb stand-alone ... high resolution images from local or remote ... fast and easy. The camera operates independently ... PC or special software required to capture ...
... systems for very low light levels. Both ... the most demanding cases, we recommend our ... high resolution (1 million pixels), and cryogenic ... use, achieves ultra-cold temperatures without liquid nitrogen, ...
Medicine Products: